3 Undervalued Health Care Providers & Services Stocks for Thursday, July 30
Discover the top 3 undervalued Health Care Providers & Services stocks for Thursday, July 30 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Commentary & Analysis
Is DaVita Inc. (DVA) Overvalued?
We dive into why DaVita Inc. (DVA) could be considered overvalued on 2026-07-21, based on AAII’s Value Score and Grade.Tudor Pop
3 Undervalued Health Care Providers & Services Stocks for Thursday, June 25
Discover the top 3 undervalued Health Care Providers & Services stocks for Thursday, June 25 based on AAII’s Stock Grades.Jenna Brashear
5 Undervalued Health Care Providers & Services Stocks for Monday, May 25
Discover the top 5 undervalued Health Care Providers & Services stocks for Monday, May 25 based on AAII’s Stock Grades.Jenna Brashear
Which Is a Better Investment, DaVita Inc. or Elevance Health, Inc. Stock?
Learn more about whether DaVita Inc. or Elevance Health, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | DVA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15,334.8 | $1,875.0 | 83% |
|
| Shares Out (Mil) | 68.9 | 77.1 | 55% |
|
| Institutional Ownership | 96.8% | 88.9% | 71% |
|
| Float (Mil) | 34.2 | 50.3 | 39% |
|
| Beta | 0.91 | 0.86 | 54% |
|
| Avg Daily Volume (000s) | 591 | 466 | 62% |
|
| Price Change (52-week) |
63.6% | 78.5% | 85% |
|
| Growth | DVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.4% | 10.9% | 28% |
|
| Net Income (5yr) | (0.7%) | (1.1%) | 39% |
|
| EPS (5yr) | 9.3% | 3.0% | 45 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 22.6% | (18.2%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 7 | 8 | |
| Current EPS | $3.882 | $14.826 | $17.222 | |
| Month Ago EPS | $3.843 | $14.798 | $17.182 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $3.628 | $14.121 | $16.399 | |
| Year/Year Chg | 35.3% | 55.9% | 108.0% | |
| Financials | DVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $13,835 | $1,464 | 87% |
|
| Net Income (TTM) (Mil) | $781 | $15 | 84% |
|
| EPS (TTM) | $10.970 | $0.300 | 95% |
|
| Operating Cash Flow (TTM) (Mil) | $2,027 | $138 | 88% |
|
| Net Cash Flow (TTM) (Mil) | $202 | $7 | 85% |
|
| Long-Term Debt (Q1) (Mil) | $12,676 | $323 | 93% |
|
| Enterprise Value (Q1) (Mil) | $27,775 | $2,130 | 87% |
|
| Valuation | DVA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.90 | na |
|
| P/E | 23.0 | 26.8 | 57% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 2.8 | 1.1 | 76% |
|
| Ratios | DVA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 32.5% | 27.6% | 39% |
|
| Net Margin | 5.6% | 1.1% | 50% |
|
| ROA | 4.5% | 1.8% | 70% |
|
| ROE | (152.8%) | 6.9% | 6% |
|
| Liabilities to Assets | 94.0% | 60.0% | 91% |
|
| F-Score | 7 | 5 | 84% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.5 |
